Multiple Myeloma With a Rare Presentation at Preserved Uninvolved Immunoglobulins.

Introduction

Multiple myeloma is a neoplastic lesion caused by mature immunoglobulin-producing plasma cells and is characterized by the presentation of hypercalcemia, renal dysfunction, anemia, and bone lesions (CRAB features) as organ damage features. Normal plasma cells produce various subtypes of immunoglobulins such as IgG, IgM, and IgA, while myeloma cells are characterized by the production of monoclonal immunoglobulin (M-protein). Furthermore, as myeloma proliferates in the bone marrow, normal plasma cells are reduced, and the production of uninvolved immunoglobulins other than M-protein is suppressed. As a result, multiple myeloma is associated with immune paresis and a high risk of bacterial and viral infections [ 1 ]. Protein electrophoresis (SPEP), immunofixation (IFE), and free light chain assay (FLC) of the serum are very sensitive and almost all are diagnosed as monoclonal gammopathy of undetermined significance (MGUS), although it is found in a few percent of patients over 50 years of age when performed as a screening test [ 2 - 4 ]. Of these, approximately 0.5-1% per year would progress to multiple myeloma in the future, and even over a 30-year course, only about 30% would develop multiple myeloma [ 5 - 7 ]. This means that the majority of patients diagnosed with MGUS could be likely to die before progressing to myeloma and requiring treatment. Because SPEP, IFE, and FLC as screening tests could be overdiagnosed, these tests are only performed in cases of strongly suspected symptomatic multiple myeloma. However, a symptom such as the CRAB feature seen in multiple myeloma is very common in the elderly and is more often caused by diseases other than myeloma. Therefore, even when M-protein is detected, the question arises as to whether it is due to multiple myeloma. Therefore, quantitative immunoglobulin assay by nephelometer is often used to estimate the presence of tumor cell proliferation in the bone marrow based on whether the production of normal immunoglobulins other than M-protein is suppressed. A previous report showed that normal immunoglobulins were suppressed in 90% of multiple myeloma cases [ 8 ], but only 30% of MGUS [ 5 ]. It can also be inferred from the fact that hypergammaglobulinemia due to non-neoplastic diseases seen in chronic inflammatory diseases, liver cirrhosis, and nephrotic syndrome is elevated in all isotypes. However, we report here a case of hypercalcemia and pain associated with bone lesions in a patient with clear symptomatic myeloma who did not show normal immunoglobulin suppression and required a longer time to be diagnosed.

Case presentation

A 67-year-old woman had a slight fever of 37°C and chest pain on the left side for a month. Her doctor prescribed painkillers and vitamins for intercostal neuralgia. She had persistent pain and a fever over 38°C for a week, so she visited our emergency room on Sunday. Computed tomography (CT) showed a slight infiltration shadow in S8’s left lung and oral antimicrobial agents were started with the diagnosis of left pneumonia and pleurisy. Another week later, in addition to fever, hypercalcemia was noted with serum-corrected calcium of 12.7 mg/dl. The patient had pleurisy refractory to antimicrobial agents, and hypercalcemia due to pleural involvement by tuberculous pleuritis or neoplastic disease was suspected. Because hypercalcemia required correction for infusion, the patient was admitted to the hospital for a thorough examination. Tuberculous pleurisy was ruled out due to a negative Interferon Gamma Release Assay. In addition to hypercalcemia, multiple myeloma was also suspected because of mild renal impairment and anemia. However, the serum immunoglobulin IgG subtype was slightly increased, and other subtypes (IgM, IgA) were not suppressed. As a result, we ruled out the possibility of myeloma at this point. CT and chest X-ray was performed again, which showed progressive infiltration shadow and increased pleural effusion (Figure 1 ), leading to a strong suspicion of malignant lung or pleural disease.

We consulted respiratory medicine. Bronchoscopy was performed for left S8’s lesion but found only nonspecific inflammatory findings. About a month and a half after the initial visit, lumbar back pain appeared again, and a lumbar magnetic resonance imaging (MRI) was performed, which showed a high-signal pattern in the lumbar vertebral body at T2 emphasized image and short inversion time inversion recovery (STIR) image (Figure 2 ).

On the other hand, there was no evidence of bone destruction, and a hematopoietic tumor was suspected rather than bone metastasis of cancer. The hypercalcemia and pain associated with the bone lesions suggested the possibility of multiple myeloma, and immunoglobulin measurements revealed only a mild increase in IgG and no suppression of other immunoglobulins. Quantitation of immunoglobulins is seen in Table 1 .

However, serum protein fractionation on cellulose membranes suggested the presence of M-protein, and immunofixation revealed IgG-κ-type M-protein. A bone marrow examination performed by the hematologist showed a remarkable increase in monotonous plasma cells (Figure 3 ).

Positron emission tomography-computed tomography (PET-CT) showed diffuse accumulation in the bones throughout the body (Figure 4 ).

She was finally diagnosed with symptomatic multiple myeloma. She was treated with BD regimen (bortezomib 1.3mg/m 2 , day 1, 4, 8, 11 dexamethasone 20mg/body, day 1, 4, 8, 11) and DBD regimen (daratumumab 16mg/kg, day 1, 8, 15; bortezomib 1.3mg/m 2 ; day 1, 4, 8, 11 dexamethasone 20mg/body, day 1, 2, 4, 5, 8, 9, 11, 12) at the Department of Hematology, but myeloma progressed. She was switched to an ELD regimen (elotuzumab 10mg/kg, day 1, 8, 15, 22, dexamethasone 28mg/kg, day 1, 8, 15, 22) and achieved a very good partial response, but complications of severe infection in the second cycle required hospitalization. After that, the patient was unable to continue treatment due to a decline in performance status, and only palliative care using steroids alone was provided. She died approximately six and a half months after our first visit for myeloma progression.

Discussion

This patient presented with a fever of unknown origin that persisted for more than three months and was eventually diagnosed with multiple myeloma. It took about two months from the initial diagnosis to the definitive diagnosis, making this a difficult case to diagnose. The patient had left-sided chest pain as an accompanying symptom and a very small amount of pleural effusion on X-ray and CT, which may have contributed to our recommendation to focus on pleural disease for differentiation. During the disease, the patient developed hypercalcemia, and multiple myeloma was suggested as a possible diagnosis. However, since IgG was only mildly elevated in the serum immunoglobulin quantitative test and other immunoglobulins such as IgA and IgM were not suppressed, we judged that the patient had polyclonal hypergammaglobulinemia associated with chronic inflammation and did not search for clonality by SPEP, IFE and FLC assay. Anemia was also present since the initial visit, but since it was thought to be a fever of unknown origin, it was judged to be anemia associated with chronic inflammation. Iron kinetic tests also showed decreased iron (Fe) and total iron-binding capacity (TIBC) and increased ferritin, which was consistent with anemia associated with chronic inflammation. Two of the CRAB features for multiple myeloma were applicable, but the absence of normal immunoglobulin suppression ruled out myeloma altogether, which contributed to the delay in diagnosis.

The diagnosis of multiple myeloma is generally based on three factors: (1) the presence of M-protein; (2) an increase in plasma cells in the bone marrow; and (3) the presence of organ damage such as hypercalcemia, anemia, renal damage, and bone lesions. Generally, M-proteins are identified by SPEP, IFE, and FLC assay. But these tests are too sensitive, and when performed as screening tests, they are often suspect-positive. The majority of these patients have MGUS with no increase in tumor cells in the bone marrow and no organ damage. Kyle et al. found that 3.2% of patients over 50 years of age were diagnosed with MGUS when SPEP was performed on residual blood serum collected at the Mayo Clinic as part of routine laboratory testing. The rate increases with age, from 5.3% in patients aged 70 years and older to 7.5% in patients aged 85 years and older [ 2 ]. Furthermore, Landgren et al. reported that in the general population, the prevalence of MGUS is 2.4% in those over 50 years of age, and by race, it is more common in blacks than in Hispanics or whites [ 4 ]. Although 0.5-1% of patients develop multiple myeloma each year, with a 30-year risk of progression [ 5 - 7 ], only a small percentage of patients are eligible for treatment, and many cases require follow-up for decades, which is excessive in terms of patient and healthcare professional burden and cost. It is essential to diagnose multiple myeloma requiring treatment at the appropriate time and without delay. We have used quantitation of immunoglobulins by nephelometer as a screening test. If some or all immunoglobulin subtypes are suppressed, symptomatic myeloma is strongly suspected. Kyle et al. (2002) analyzed the characteristics of 1027 patients with newly diagnosed multiple myeloma and reported that 91% had one or more normal immunoglobulins suppressed [ 8 ]. On the other hand, MGUS followed up for 20~35 years reported that only 29% had suppressed normal immunoglobulins [ 5 ]. Quantitation of immunoglobulins by nephelometer is very convenient for screening because they can often be easily measured at one's facility and the results are immediately available in a short time. The overdiagnosis of MGUS can be reduced by performing quantitation of immunoglobulins by nephelometer and adding SPEP, IFE, and FLC assay only when uninvolved immunoglobulins are suppressed to aggressively search for and confirm the presence of M-proteins. However, as in this present case, uninvolved immunoglobulins are not suppressed in about 10% of symptomatic myeloma, so caution should be exercised when using this method for exclusion diagnosis. In our case, the patient had gradually increased back pain, and a lumbar MRI scan was performed to reexamine the possibility of myeloma. When symptoms are present that cannot be explained by other diseases, more sensitive IFE and FLC assay should be used in combination.

The preservation of uninvolved immunoglobulin has been reported as a favorable prognostic factor in multiple myeloma. E Kastritis et al. compared 1755 patients with multiple myeloma whose serum immunoglobulins were measured in a Greek database with and without preserved uninvolved immunoglobulin [ 9 ]. Jennifer L. J. Heaney et al. showed similar results using a dataset of 5826 multiple myeloma patients in the United Kingdom [ 10 ]. It was reported that suppression of the IgM subtype is influenced by overall survival. Chuanying Geng et al. report 278 single-center multiple myeloma patients from China, but propensity score matching was performed and cytogenetic including R-ISS and other characteristics, which have also been shown to be independent prognostic factors [ 11 ]. A different immunoassay with nephelometer using the HLC® assay, which can measure subsets of immunoglobulin heavy and light chains, has also reported that the preservation of uninvolved immunoglobulins is a favorable prognostic factor associated with overall survival [ 12 , 13 ]. Reports from a Danish registry and a single center in Turkey have not shown an association between the presence of suppression of uninvolved immunoglobulin and survival, but progression-free survival in the Danish report tended to be similar [ 14 , 15 ]. In the present case, the patient had IgG-κ myeloma, but died rapidly about 6.5 months after diagnosis despite the levels of both IgM and IgA subtypes being within normal range; R-ISS corresponded to stage II, and no poor prognostic chromosomal abnormalities were detected by FISH. No poor prognostic factors other than age over 65 years and low PS 1~2 were found among the previously reported poor prognostic factors. The response to treatment with the bortezomib regimen was also poor. It may suggest that there are still unknown poor prognostic factors in our case.

Conclusions

Screening for suspected symptomatic myeloma by quantitation of immunoglobulins is a simple and useful method to prevent overdiagnosis of MGUS and to identify symptomatic myeloma requiring treatment. It should be noted, however, that approximately 10% of multiple myeloma cases have preservation of uninvolved immunoglobulins. When symptoms such as CRAB feature are present and cannot be explained by other common diseases or pathologies, M-protein should be searched for by a more sensitive IFE or serum FLC assay. In addition, the preservation of uninvolved immunoglobulin in multiple myeloma at initial diagnosis has been reported as an independent favorable prognostic factor. However, in this case, the patient was refractory to treatment and had a poor prognosis. This patient’s clinical course could not be clearly explained by poor prognostic factors already reported. Therefore, we suppose that there may be unknown factors, and further case accumulation and investigation are needed.

The authors have declared that no competing interests exist.

Human Ethics

Consent was obtained or waived by all participants in this study

References

1 Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients Haematologica Blimark C Holmberg E Mellqvist UH 107 113 100 2015 25344526 10.3324/haematol.2014.107714 PMC4281323

2 Prevalence of monoclonal gammopathy of undetermined significance N Engl J Med Kyle RA Therneau TM Rajkumar SV 1362 1369 354 2006 16571879 10.1056/NEJMoa054494

3 Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study Lancet Dispenzieri A Katzmann JA Kyle RA 1721 1728 375 2010 20472173 10.1016/S0140-6736(10)60482-5 PMC2904571

4 Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey Leukemia Landgren O Graubard BI Katzmann JA 1537 1542 28 2014 24441287 10.1038/leu.2014.34 PMC4090286

5 "Benign" monoclonal gammopathy--after 20 to 35 years of follow-up Mayo Clin Proc Kyle RA 26 36 68 1993 8417251 10.1016/s0025-6196(12)60015-9

6 A long-term study of prognosis in monoclonal gammopathy of undetermined significance N Engl J Med Kyle RA Therneau TM Rajkumar SV Offord JR Larson DR Plevak MF Melton LJ 3rd 564 569 346 2002 11856795 10.1056/NEJMoa01133202

7 Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden Blood Turesson I Kovalchik SA Pfeiffer RM Kristinsson SY Goldin LR Drayson MT Landgren O 338 345 123 2014 24222331 10.1182/blood-2013-05-505487 PMC3894492

8 Review of 1027 patients with newly diagnosed multiple myeloma Mayo Clin Proc Kyle RA Gertz MA Witzig TE 21 33 78 2003 12528874 10.4065/78.1.21

9 Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma Leukemia Kastritis E Zagouri F Symeonidis A 2075 2079 28 2014 24637336 10.1038/leu.2014.110

10 Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials Leukemia Heaney JL Campbell JP Iqbal G 1727 1738 32 2018 29925902 10.1038/s41375-018-0163-4 PMC6087716

11 Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients Leuk Lymphoma Geng C Yang G Wang H 883 890 62 2021 33275060 10.1080/10428194.2020.1855345

12 Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients Br J Haematol Harutyunyan NM Vardanyan S Ghermezi M Gottlieb J Berenson A Andreu-Vieyra C Berenson JR 81 87 174 2016 27017948 10.1111/bjh.14026

13 Heavy/light chain assay in the monitoring of multiple myeloma Pathology Ting HY Sthaneshwar P Bee PC Shanmugam H Lim M 507 511 51 2019 31253381 10.1016/j.pathol.2019.04.002

14 Immunoparesis in newly diagnosed multiple myeloma patients: effects on overall survival and progression free survival in the Danish population PLoS One Sørrig R Klausen TW Salomo M 0 12 2017 10.1371/journal.pone.0188988 PMC5720701 29216227

15 The effect of suppressed levels of uninvolved immunoglobulins on the prognosis of symptomatic multiple myeloma Turk J Haematol Sarı M Sarı S Nalçacı M 131 136 34 2017 27795224 10.4274/tjh.2016.0161 PMC5440864